レムデシビルで治療された呼吸不全合併COVID-19 7 例において観察された臨床的効果と有害事象について

書誌事項

タイトル別名
  • Clinical Efficacy and Adverse Event of Remdesivir Treatment in Seven COVID-19 Cases with Respiratory Failure

この論文をさがす

抄録

<p>A preliminary report from a global study showed that remdesivir, a nucleoside analog pro-drug that was originally developed as a therapeutic drug against Ebola virus, may exert clinical efficacy in cases of COVID-19, by shortening the time to recovery. We had the opportunity to use this new drug in the treatment of 7 COVID-19 patients with respiratory failure.</p>

収録刊行物

  • 感染症学雑誌

    感染症学雑誌 95 (2), 147-152, 2021-03-20

    一般社団法人 日本感染症学会

参考文献 (8)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ